CClinicalTrials.gg
CompletedNCT04729530Updated Aug 5, 2022

The Effect of Dyson Air Purifier in Improving Asthma Control

An interventional study of Dyson Pure Cool - Active Purifier and Dyson Pure Cool - Placebo purifier in Asthma, sponsored by The David Hide Asthma & Allergy Research Centre. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-08-05.

Sponsored by The David Hide Asthma & Allergy Research Centre · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

To investigate the effect of reducing the level of allergens and pollutants in the bedroom and living room by placing a "Dyson air purifier", on poorly controlled asthmatic subjects.

Read the detailed description

Asthma is one of the most common chronic diseases. Little change in morbidity and mortality has occurred despite improvements in pharmacotherapy. In the last few decades, there has been an increase in the prevalence of asthma and other allergic diseases. The precise cause for this increase in disease prevalence is not known but it has coincided with changes to the quality of indoor air with increases in the levels of allergens and pollutants. Bedroom exposure to dust-mite allergens has been linked to worsening asthma symptoms and increase in bronchial responsiveness. In places where dust mites cannot thrive, allergens from cat, cockroach and Alternaria assume importance. High indoor temperatures and humidity may, by a number of mechanisms, increase the allergenic burden, particularly the proliferation of house-dust mites and moulds. Therefore, modern living conditions are associated with a higher risk of allergen exposure causing increase in sensitisation and symptoms of asthma. In addition to allergens, the indoor environment contains other biological materials (such as microbiome and endotoxin), and pollutants (gases and particulate matter) which can adversely affect asthma development and morbidity. Indoor pollutants include smoke from cigarettes and wood, coal or gas fires, particulate materials associated with bio-fuel combustion, chemical vapours and gases including nitrogen dioxide (NO2), formaldehyde and volatile organic compounds (VOCs). The latter may come from sources including building products, cleaning agents, and paints. One such VOC is formaldehyde, which can be irritant to both upper and lower respiratory tract. Small particulate matter (PM2.5) is particularly damaging as it gets to the small airways of the lung. Major indoor sources of NO2 and particulate matter include gas stoves and cigarette smoke but outdoor sources such as traffic and industrial pollution can also contaminate indoor environment.

It has also been suggested that exposure to pollutants can potentiate the effects of allergen. Indeed, a combination of high levels of indoor pollution and allergens is causally related to the development and severity of asthma. Allergens, microbiome and pollutants can interact with each other to augment the immune response leading to harmful effects on the airways.

Thus, indoor air pollution is a significant environmental trigger for acute exacerbation of asthma (and other respiratory conditions such as COPD), leading to increasing symptoms, emergency department visits, hospital admissions and even mortality. An estimated 75% of hospital admissions for asthma are avoidable. Maintaining high air quality with lower levels of allergens and pollutants is therefore important in improving the health of individuals with asthma and other respiratory diseases. Therefore, a feasible and practical intervention that can reduce allergen and pollutant levels in the indoor air should reduce morbidity and improve asthma control.

02

Conditions studied

  • Asthma

Browse trials for

03

In context

Asthma

3,921 studies on the registry are indexed under Asthma; 507 are open to participants now.

This study's enrollment of 50 is below the median of 83 across 2,752 interventional studies indexed under Asthma.

Browse Asthma studies →

Lead sponsor

This is the only study on the registry with The David Hide Asthma & Allergy Research Centre as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients between 18 to 75 years of age with a confirmed diagnosis of mild persistent to moderate persistent asthma (BTS steps "regular preventer therapy" to "additional add-on therapies")
  • ACQ6 score >1.5.

Exclusion criteria

Exclusion Criteria:

  • Patients with significant chronic respiratory disease such as COPD or bronchiectasis.
  • Patients with any severe disease (such as cardiovascular disease, dementia etc.), where adherence to the study protocol may cause an unjustified stress.
  • Those who are being treated with allergen specific immunotherapy.
  • Patients with a history of significant alcohol or drug abuse.
  • Patients who are taking an investigational drug for asthma.
  • Patients who are unwilling, unlikely or unable to comply with the study protocol, as assessed by the study team members.
  • Patients who are likely to be started on biological therapies for asthma (omalizumab, mepolizumab, reslizumab, dupilumab) during the study period.
  • Pregnancy.
  • Patients already using air purifiers in their dwellings.
  • Patients planning to move house during the study period.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Active comparator
    Active

    Air purifier device with standard filter cartridges installed.

    Device: Dyson Pure Cool - Active Purifier

  • Placebo comparator
    Placebo

    Air purifier device with placebo (non working) filter cartridges installed.

    Device: Dyson Pure Cool - Placebo purifier

Interventions

  • DeviceDyson Pure Cool - Active Purifier

    Free standing air purifier

  • DeviceDyson Pure Cool - Placebo purifier

    Placebo air purifier

06

What researchers measure

Primary outcomes

  1. Change in asthma quality of life score

    Change in Juniper asthma specific quality of life (AQLQ) scores: A change in score of 0.5 on the 7-point scale is considered clinically important (Minimal Important Difference).

    Time frame: 18 months

  2. Change in asthma control score

    Change in asthma control composite scores using Juniper asthma control questionnaire (ACQ6). A change in score of 0.5 on the 6-point scale is considered clinically important.

    Time frame: 18 months

Secondary outcomes

  1. Change in airway responsiveness

    Change in airway responsiveness from baseline will be compared in the two groups (as assessed by methacholine bronchial challenge).

    Time frame: 18 months

  2. Change in indoor pollutant level

    Changes in indoor levels of pollutants that are recorded by Dyson purifier.

    Time frame: 18 months

  3. Pulmonary function: forced expiratory volume in one second (FEV1)

    Pulmonary function as assessed by changes in forced expiratory volume in one second (FEV1),

    Time frame: 18 months

  4. Pulmonary function: FEV1 (forced expiratory volume in one second) /FVC (Forced Vital Capacity) ratio

    Pulmonary function as assessed by changes FEV1/FVC (Forced Vital Capacity) ratio

    Time frame: 18 months

  5. Pulmonary function: mid-expiratory flows.

    Pulmonary function as assessed by changes in mid expiratory flows.

    Time frame: 18 months

  6. Exhaled Nitric Oxide

    Change in exhaled nitric oxide levels (as an indicator of airway inflammation) from baseline will be compared in the two groups.

    Time frame: 18 months

  7. Peak expiratory flow

    Change in peak expiratory flow from baseline will be compared in the two groups.

    Time frame: 18 months

07

Study locations

1 site
  • The David Hide Asthma and Allergy Research Centre
    Newport, Isle Of Wight PO30 5TG, United Kingdom
08

References and documents

Publications

  • Fong WCG, Grevatt S, Potter S, Tidbury T, Kadalayil L, Bennett K, Larsson M, Nicolas F, Kurukulaaratchy R, Arshad SH. The Efficacy of the Dyson Air Purifier in Improving Asthma Control: Protocol for a Single-Center, Investigator-Led, Randomized, Double-Blind, Placebo-Controlled Trial. JMIR Res Protoc. 2021 Jul 27;10(7):e28624. doi: 10.2196/28624. PubMed 34313599 ↗

Study documents

  • Informed consent form · Jun 14, 2019

Documents are hosted by the registry — open the source record to download them.

Individual participant data

Plan to share: No

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Aug 5, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04729530
Lead sponsor
The David Hide Asthma & Allergy Research Centre
Collaborators
Isle of Wight NHS Trust
Responsible party
Sponsor
First posted
Jan 28, 2021
Start date
Sep 3, 2019
Primary completion
Jul 21, 2021
Completion
Jul 21, 2021
Last update
Aug 5, 2022

Study contacts

S. Hasan Arshad
principal investigator · University of Southampton

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion